Citizens JMP analyst lvan Tuerkcan initiated coverage of Ideaya Biosciences (IDYA) with an Outperform rating and $41 price target Ideaya is a clinical-stage biotechnology company focused on developing novel therapies in oncology, the analyst tells investors in a research note. The firm says the company’s synthetic lethality platform has created a broad pipeline of targeted therapies with established or de-risked mechanisms of action.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences initiated with an Overweight at Barclays
- Hold Rating for IDEAYA Biosciences Amid Favorable Financial Terms and Developmental Risks
- Ideaya Biosciences price target raised to $74 from $72 at JPMorgan
- Ideaya Biosciences submits IDE892 IND application to FDA
- IDEAYA Biosciences: Strategic Partnership with Servier Bolsters Financial Outlook and Validates Darovasertib Potential